Oslo, 9 April 2026: Lytix Biopharma AS (the "Company") has granted 100,000 share options to primary insider Darlene Deptula-Hicks, a member of the Company's board of directors, under the Company's long-term incentive program, as approved by the extraordinary general meeting on 26 January 2026.
Each option gives the right to acquire one share in the Company at an exercise price of NOK 9.94. The options are granted without consideration, are subject to vesting over a four-year period, and have a term of five years from the grant date.
Please see the attached notification form for further details.
For further information, please contact:
Gjest Breistein, CFO
Email: gjest.breistein@lytixbiopharma.com
This announcement is made pursuant to section 5-12 of the Norwegian Securities Trading Act and Article 19 of the EU Market Abuse Regulation.